{"product_id":"anti-gef-h1-rabbit-monoclonal-antibody-bha21009426","title":"Anti-GEF H1 Rabbit Monoclonal Antibody","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eThis product is an anti-ARHGEF2 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone 19A27; isotype IgG; reactivity: Human,Mouse,Rat. Reported application contexts include WB, ICC, IF, Flow (as provided in the source record). Boster Bio Anti-GEF H1 Rabbit Monoclonal Antibody catalog # M02572-1. Tested in WB, ICC\/IF, Flow Cytometry applications. This antibody reacts with Human, Mouse, Rat.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e ARHGEF2 (Proline-, glutamic acid- and leucine-rich protein 1).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAntibody format:\u003c\/strong\u003e Monoclonal; clone 19A27; isotype IgG.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHost:\u003c\/strong\u003e Rabbit.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e Human,Mouse,Rat (confirm in your model system with appropriate controls).\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThis description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.\u003c\/p\u003e \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eARHGEF2 (protein: T-cell surface glycoprotein CD3 zeta chain) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Coactivator of estrogen receptor-mediated transcription and a corepressor of other nuclear hormone receptors and sequence- specific transcription factors. Plays a role in estrogen receptor (ER) genomic activity when present in the nuclear compartment by activating the ER target genes in a hormonal stimulation dependent manner. Can facilitate ER non-genomic signaling via SRC and PI3K interaction in the cytosol. Plays a role in E2-mediated cell cycle progression by interacting with RB1. May have important functional implications in ER\/growth factor cross-talk. Interacts with several growth factor signaling components including EGFR and HRS. Involved in nuclear receptor signaling via its interaction with AR and NR3C1. May promote tumorigenesis via its interaction with and modulation of several oncogenes including SRC, PI3K, STAT3 and EGFR. Plays a role in cancer cell metastasis via its ability to modulate E2-mediated cytoskeleton changes and cell migration via its interaction with SRC and PI3K. Functions as the key stabilizing component of the Five Friends of Methylated CHTOP (5FMC) complex; the 5FMC complex is recruited to ZNF148 by methylated CHTOP, leading to desumoylation of ZNF148 and subsequent transactivation of ZNF148 target genes. . Reported cellular localization context: Nucleus, nucleoplasm . Nucleus. Cytoplasm. Mainly found in the nucleoplasm, with low levels detected in the cytoplasm (By similarity). Also found associated with the plasma membrane. Mainly in cytoplasm in a subset of breast tumors. Localization is widely deregulated in endometrial cancers with predominantly cytoplasm localization in high-grade endometrial tumors. . Tissue expression notes (as provided): Widely expressed. .\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eResearch context keywords from the source record include: Epigenetics and Nuclear Signaling,2339.\u003c\/li\u003e\n\u003cli\u003eCurrent studies often focus on connecting target abundance\/localization to pathway perturbations across models, tissues, and cell states.\u003c\/li\u003e\n\u003cli\u003eQuantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eWestern blotting (WB):\u003c\/strong\u003e assess relative target abundance across samples, treatments, or time-points.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunofluorescence\/ICC (IF\/ICC):\u003c\/strong\u003e visualize subcellular localization patterns and cell-to-cell heterogeneity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFlow cytometry:\u003c\/strong\u003e quantify target-positive populations and compare shifts in marker distributions.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eWorkflow ideas (metafield): Validate ARHGEF2 antibody specificity using KO\/KD control samples (WB\/IF\/IHC as appropriate), Detect ARHGEF2 expression by Western blot in cell or tissue lysates, Localize ARHGEF2 by immunofluorescence\/immunocytochemistry in cultured cells, Quantify ARHGEF2-positive cells by flow cytometry in single-cell suspensions\u003c\/p\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eConsider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.\u003c\/li\u003e\n\u003cli\u003eApparent molecular weight may vary by sample type and processing (observed MW: 112 kDa; calculated MW: 119700 MW).\u003c\/li\u003e\n\u003cli\u003eControl concepts: include appropriate negative controls (e.g., isotype, KO\/KD samples) and orthogonal validation when feasible.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eAdditional product details (from the source record)\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight (observed):\u003c\/strong\u003e 112 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCellular localization (provided):\u003c\/strong\u003e Nucleus, nucleoplasm . Nucleus. Cytoplasm. Mainly found in the nucleoplasm, with low levels detected in the cytoplasm (By similarity). Also found associated with the plasma membrane. Mainly in cytoplasm in a subset of breast tumors. Localization is widely deregulated in endometrial cancers with predominantly cytoplasm localization in high-grade endometrial tumors. .\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTissue details (provided):\u003c\/strong\u003e Widely expressed. .\u003c\/li\u003e\n\u003c\/ul\u003e \u003c!-- Sources (internal): - Antibodies — a laboratory manual overview — Cold Spring Harbor Protocols — https:\/\/cshprotocols.cshlp.org\/ - UniProt Knowledgebase — UniProt — https:\/\/www.uniprot.org\/ - NCBI Gene — NCBI — https:\/\/www.ncbi.nlm.nih.gov\/gene\/ - Antibody validation and reproducibility — Nature methods (collections) — https:\/\/www.nature.com\/collections\/ - Immunohistochemistry\/Immunofluorescence basics — NIH \/ NCBI Bookshelf — https:\/\/www.ncbi.nlm.nih.gov\/books\/ --\u003e","brand":"Boster Bio","offers":[{"title":"100 uL\/vial \/ Unconjugated","offer_id":53071971516781,"sku":"M02572-1","price":370.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/m02572-1-wb7.jpg?v=1772618994","url":"https:\/\/www.ebiohippo.com\/products\/anti-gef-h1-rabbit-monoclonal-antibody-bha21009426","provider":"BioHippo","version":"1.0","type":"link"}